Study Details: Safety, efficacy and dosage of CCNU in combination with toceranib
Tumor type: All but Mast Cell Tumors
Purpose of study: The purpose of this study is to determine the safety, efficacy, and maximum tolerated dose of CCNU (lomustine) when given in combination with toceranib (Palladia) in tumor-bearing dogs (other than mast cell tumors). Prior surgery and chemotherapy is acceptable with the exception of prior treatment with toceranib or CCNU. Dogs that have received toceranib or CCNU are not eligible for this study. All dogs will receive toceranib, CCNU, and denamarin (a drug which protects the liver from potential side effects that have been associated with CCNU). The dose of CCNU will be increased as dogs are entered into this trial so that we can determine the maximum tolerated dose of CCNU when given in combination with toceranib.
For additional information: Click Here or please contact Dr. Kathleen Tsimbas or members of the Oncology Service at (608) 263-7600.